Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

This study has been withdrawn prior to enrollment.
(never initiated, did different study)
Information provided by (Responsible Party):
Cheryl McCullumsmith, University of Alabama at Birmingham Identifier:
First received: August 7, 2012
Last updated: May 26, 2015
Last verified: May 2015
This study is dedicated to achieving a better understanding of how the brain processes information. Specifically, the investigators are studying cognitive function, thought process, and impulsivity in people with and without suicidal thoughts. You are being asked to participate in a research study to learn how the use of a medication, risperidone, improves your symptoms of depression. Specifically the investigators are studying the effectiveness of reducing the thought of suicide and other symptoms of severe depression. Risperidone is approved by FDA for the treatment of schizophrenia and bipolar mania, and clinical practice suggests that it might benefit patients with major depressive disorder. During clinical trials with 2607 patients, risperidone was proved to be safe. This is a pilot study to test a new indication of risperidone for treatment of severe depression. The study medication will be given in addition to usual psychiatric care.

Condition Intervention
Active Suicidal Ideation
Other: placebo
Drug: Riperidone

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Participant)
Primary Purpose: Treatment
Official Title: Assessment and Treatment of Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression.

Resource links provided by NLM:

Further study details as provided by Cheryl McCullumsmith, University of Alabama at Birmingham:

Primary Outcome Measures:
  • Decrease in depression symptoms [ Time Frame: baseline to 5 days ]

Enrollment: 0
Study Start Date: April 2010
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Risperidone
Administer pill of risperidone 1 mg once a day by mouth for 5 days.
Drug: Riperidone
1 mg risperidone administered orally for 5 days
Other Name: risperdal
Placebo Comparator: Placebo
Administer pill of placebo once a day by mouth for 5 days.
Other: placebo
placebo pill administered daily for 5 days

  Show Detailed Description


Ages Eligible for Study:   19 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age : 19-64
  • Suicidality score of > 4 on Montgomery-Asberg Depression Rating Scale (MADRS)

Exclusion Criteria:

  • pregnant,
  • medically unstable,
  • history of schizophrenia,
  • schizoaffective disorder,
  • bipolar disorder,
  • psychosis NOS,
  • urine drug screen positive for cocaine,
  • marijuana or amphetamines,
  • withdrawal from opiates,
  • benzodiazepines or alcohol,
  • currently on antipsychotic drug therapy. Also excluded are those subjects who require the use of mood stabilizers or antipsychotics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01770600

United States, Alabama
University of Alabama Birmingham
Birmingham, Alabama, United States, 35294
Sponsors and Collaborators
University of Alabama at Birmingham
Principal Investigator: Cheryl B McCullumsmith, MD PhD University of Alabama at Birmingham
  More Information

Responsible Party: Cheryl McCullumsmith, Division Director, Hospital Psychiatry, University of Alabama at Birmingham Identifier: NCT01770600     History of Changes
Other Study ID Numbers: F1003310002
Study First Received: August 7, 2012
Last Updated: May 26, 2015

Keywords provided by Cheryl McCullumsmith, University of Alabama at Birmingham:
Age 19 to 64
Medically stable
No current or history of psychosis
No alcohol or benzodiazepine withdrawal

Additional relevant MeSH terms:
Depressive Disorder
Impulsive Behavior
Suicidal Ideation
Behavioral Symptoms
Mood Disorders
Mental Disorders
Self-Injurious Behavior
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents processed this record on May 25, 2017